Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
| Texto Completo: | https://www.arca.fiocruz.br/handle/icict/51167 |
Resumo: | Instituto Nacional de Alergia e Doenças Infecciosas para N.E.D. |
| id |
CRUZ_8555b973a1bb2dd955fba5b4a888c27a |
|---|---|
| oai_identifier_str |
oai:www.arca.fiocruz.br:icict/51167 |
| network_acronym_str |
CRUZ |
| network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| repository_id_str |
2135 |
| spelling |
Hitchings, Matt D. T.Ranzani, Otavio T.Lind, Margaret L.Dorion, MuriloD’Agostini, Tatiana LangPaula, Regiane Cardoso dePaula, Olivia Ferreira Pereira deVillela, Edlaine Faria de MouraTorres, Mario Sergio ScaramuzziniOliveira, Silvano Barbosa deSchulz, WadeAlmiron, MariaSaid, RodrigoOliveira, Roberto Dias deSilva, Patricia Vieira daAraújo, Wildo Navegantes deGorinchteyn, Jean CarloDean, Natalie E.Andrews, Jason R.Cummings, Derek A. T.Ko, Albert I.Croda, Julio2022-02-14T12:47:12Z2022-02-14T12:47:12Z2021HITCHINGS, Matt D. T. et.al. Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study. MedRxiv preprint, p. 1-23, 2021.https://www.arca.fiocruz.br/handle/icict/5116710.1101/2021.12.23.21268335Instituto Nacional de Alergia e Doenças Infecciosas para N.E.D.University of Florida. Department of Biostatistics. College of Public Health & Health Professions. Gainesville, FL, USA.Barcelona Institute for Global Health. ISGlobal. Barcelona, Spain / Universidade de São Paulo. Faculdade de Medicina. Hospital das Clínicas HCFMUSP. Pulmonary Division, Heart Institute (InCor). São Paulo, SP, Brazil.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA.Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.Disease Control Coordination of the São Paulo State Department of Health. São Paulo, SP, Brazil.Municipal Health Secretary of Manaus. Manaus, AM, Brazil.Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília. Brasília, DF, Brazil.Yale University School of Medicine. Department of Laboratory Medicine. New Haven, CT, USA.Pan American Health Organization. Brasília, DF, Brazil.Pan American Health Organization. Brasília, DF, Brazil.State University of Mato Grosso do Sul. Dourados, MS, Brazil.Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brazil.Pan American Health Organization. Brasília, DF, Brazil / Universidade de Brasília, Brasília, Distrito Federal, Brazil / National Institute for Science and Technology for Health Technology Assessment. Porto Alegre, RS, Brazil.Health Secretariat of the State of São Paulo. São Paulo, SP, Brazil.Emory University. Rollins School of Public Health. Department of Biostatistics & Bioinformatics. USA.Stanford University, Stanford. Division of Infectious Diseases and Geographic Medicine. CA, USA.University of Florida. Department of Biology. Gainesville, FL, USA / University of Florida. Emerging Pathogens Institute. Gainesville, FL, USA.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brazil.Yale School of Public Health. Department of Epidemiology of Microbial Diseases. New Haven, CT, USA / Universidade Federal de Mato Grosso do Sul. Campo Grande, MS, Brazil / Fundação Oswaldo Cruz. Fiocruz Mato Grosso do Sul. Campo Grande, Mato Grosso do Sul, Brazil.Objective To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil. Design Test negative case-control study. Setting Community testing for covid-19 in São Paulo state, Brazil. Participants Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021. Main outcome measures RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection. Results From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 testnegative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days. Conclusions In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.engMedRxivCOVID-19CoronaVacVacinasVacinas de Produtos InativadosEstudos de Casos e ControlesBrasilCOVID-19CoronaVacVaccinesVaccines, InactivatedCase-Control StudiesBrazilChange in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control studyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/51167/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALHitchings Matt etal -Change in COVID-19 risk over time.pdfHitchings Matt etal -Change in COVID-19 risk over time.pdfapplication/pdf403696https://www.arca.fiocruz.br/bitstream/icict/51167/2/Hitchings%20Matt%20etal%20-Change%20in%20COVID-19%20risk%20over%20time.pdf50cbb25477599bd14b3c68eaef8fdad5MD52icict/511672022-03-27 21:07:15.504oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-03-28T00:07:15Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
| dc.title.pt_BR.fl_str_mv |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| title |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| spellingShingle |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study Hitchings, Matt D. T. COVID-19 CoronaVac Vacinas Vacinas de Produtos Inativados Estudos de Casos e Controles Brasil COVID-19 CoronaVac Vaccines Vaccines, Inactivated Case-Control Studies Brazil |
| title_short |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| title_full |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| title_fullStr |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| title_full_unstemmed |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| title_sort |
Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study |
| author |
Hitchings, Matt D. T. |
| author_facet |
Hitchings, Matt D. T. Ranzani, Otavio T. Lind, Margaret L. Dorion, Murilo D’Agostini, Tatiana Lang Paula, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Villela, Edlaine Faria de Moura Torres, Mario Sergio Scaramuzzini Oliveira, Silvano Barbosa de Schulz, Wade Almiron, Maria Said, Rodrigo Oliveira, Roberto Dias de Silva, Patricia Vieira da Araújo, Wildo Navegantes de Gorinchteyn, Jean Carlo Dean, Natalie E. Andrews, Jason R. Cummings, Derek A. T. Ko, Albert I. Croda, Julio |
| author_role |
author |
| author2 |
Ranzani, Otavio T. Lind, Margaret L. Dorion, Murilo D’Agostini, Tatiana Lang Paula, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Villela, Edlaine Faria de Moura Torres, Mario Sergio Scaramuzzini Oliveira, Silvano Barbosa de Schulz, Wade Almiron, Maria Said, Rodrigo Oliveira, Roberto Dias de Silva, Patricia Vieira da Araújo, Wildo Navegantes de Gorinchteyn, Jean Carlo Dean, Natalie E. Andrews, Jason R. Cummings, Derek A. T. Ko, Albert I. Croda, Julio |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Hitchings, Matt D. T. Ranzani, Otavio T. Lind, Margaret L. Dorion, Murilo D’Agostini, Tatiana Lang Paula, Regiane Cardoso de Paula, Olivia Ferreira Pereira de Villela, Edlaine Faria de Moura Torres, Mario Sergio Scaramuzzini Oliveira, Silvano Barbosa de Schulz, Wade Almiron, Maria Said, Rodrigo Oliveira, Roberto Dias de Silva, Patricia Vieira da Araújo, Wildo Navegantes de Gorinchteyn, Jean Carlo Dean, Natalie E. Andrews, Jason R. Cummings, Derek A. T. Ko, Albert I. Croda, Julio |
| dc.subject.other.pt_BR.fl_str_mv |
COVID-19 CoronaVac Vacinas Vacinas de Produtos Inativados Estudos de Casos e Controles Brasil |
| topic |
COVID-19 CoronaVac Vacinas Vacinas de Produtos Inativados Estudos de Casos e Controles Brasil COVID-19 CoronaVac Vaccines Vaccines, Inactivated Case-Control Studies Brazil |
| dc.subject.en.pt_BR.fl_str_mv |
COVID-19 CoronaVac Vaccines Vaccines, Inactivated Case-Control Studies Brazil |
| description |
Instituto Nacional de Alergia e Doenças Infecciosas para N.E.D. |
| publishDate |
2021 |
| dc.date.issued.fl_str_mv |
2021 |
| dc.date.accessioned.fl_str_mv |
2022-02-14T12:47:12Z |
| dc.date.available.fl_str_mv |
2022-02-14T12:47:12Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.citation.fl_str_mv |
HITCHINGS, Matt D. T. et.al. Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study. MedRxiv preprint, p. 1-23, 2021. |
| dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/51167 |
| dc.identifier.doi.none.fl_str_mv |
10.1101/2021.12.23.21268335 |
| identifier_str_mv |
HITCHINGS, Matt D. T. et.al. Change in COVID-19 risk over time following vaccination with CoronaVac: a testnegative case-control study. MedRxiv preprint, p. 1-23, 2021. 10.1101/2021.12.23.21268335 |
| url |
https://www.arca.fiocruz.br/handle/icict/51167 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.publisher.none.fl_str_mv |
MedRxiv |
| publisher.none.fl_str_mv |
MedRxiv |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
| instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
| instacron_str |
FIOCRUZ |
| institution |
FIOCRUZ |
| reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
| collection |
Repositório Institucional da FIOCRUZ (ARCA) |
| bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/51167/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/51167/2/Hitchings%20Matt%20etal%20-Change%20in%20COVID-19%20risk%20over%20time.pdf |
| bitstream.checksum.fl_str_mv |
5a560609d32a3863062d77ff32785d58 50cbb25477599bd14b3c68eaef8fdad5 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
| repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
| _version_ |
1813008977227677696 |